Insulet Stock: Overpriced Play In The Medical Space (PODD)
seekingalpha.com
finance
2022-10-18 07:36:17

FatCamera/E+ via Getty Images In the global fight against diabetes, one of the larger players in the space to pay attention to is Insulet Corporation (NASDAQ:PODD). With its hallmark product, the Omnipod System, the company can offer a continuous delivery of insulin that offers all of the same benefits that an insulin pump therapy regime would. Financial performance achieved by the company has generally been robust, particularly when it comes to its revenue. Having said that, shares of the enterprise are looking very expensive at this point in time.
